The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC).
 
Mark Christopher Markowski
Honoraria - Clovis Oncology; Exelixis
 
Mary-Ellen Taplin
Honoraria - Abbvie; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Constellation Pharmaceuticals; GlaxoSmithKline; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Myovant Sciences; Pfizer; Pfizer; Progenics; Research to Practice; Roivant; UpToDate
Consulting or Advisory Role - Arcus Ventures (I); AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Alessa Therapeutics; Alessa Therapeutics; Amgen; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon; Jubilant Pharmaceuticals; Merck; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Laura Sena
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Aliya Lalji
No Relationships to Disclose
 
Jennifer Meyers
No Relationships to Disclose
 
Alyza Skaist
No Relationships to Disclose
 
Anuj Gupta
No Relationships to Disclose
 
Carolina Gomes-Alexandre
No Relationships to Disclose
 
Tracy Jones
No Relationships to Disclose
 
Jessica Hicks
No Relationships to Disclose
 
Sushant Kachhap
No Relationships to Disclose
 
Srinivasan Yegnasubramanian
No Relationships to Disclose
 
Angelo M De Marzo
No Relationships to Disclose
 
Samuel R. Denmeade
Research Funding - Astellas Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed to Pfizer receive patent maintenance fees
 
Emmanuel S. Antonarakis
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Sanofi; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi